In addition to the eleven proteins selected following our GSEA analysis, conventional glioma pathology markers IDH-1, ATRX, and p53, and five other candidate markers—based on published experimental evidence on the mechanisms by which glioma cells can influence neural function in their vicinity—were selected. This evidence concerns the gene IDH1 and central nervous system cancer.